Subtitle: Market Intelligence, Epigenetic Modulator Progress, and High-Purity Reagents for Chromatin Regulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C4 drug discovery and epigenetic screening. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Substrate | H4C4 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for enzymatic assays. |
View H4C4 Products |
| Gene Delivery | H4C4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View H4C4 Products |
| Benchmark Ab | Anti-H4C4 Antibody Recombinant positive control for chromatin immunoprecipitation (ChIP) and Western Blot. |
View H4C4 Products |
| Validator | H4C4 siRNA Set For knockdown verification. |
View H4C4 Products |
| Related Target A | HDAC1 Histone deacetylase 1, key epigenetic eraser acting on H4. |
View HDAC1 Products |
| Related Target B | BRD4 Bromodomain-containing protein 4, epigenetic reader recognizing acetylated H4. |
View BRD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Substrate Purity for Enzymatic Assays | High Purity (>95%) recombinant H4C4 expressed with Native Folding, Endotoxin Controlled. |
| Nucleosome Assembly Consistency | Sequence Verified histone proteins ensuring reproducible in vitro nucleosome reconstitution. |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies included for consistent ChIP and assay validation. |
| Target Specificity | Validated siRNA included for precise specificity checks in cell-based epigenetic models. |
Live H4C4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for epigenetic therapeutics is intensifying, with major players targeting the readers, writers, and erasers of histone modifications. While H4C4 (Histone H4) is primarily a structural target and assay substrate, drugs modulating its acetylation and methylation state represent a massive oncology market. As first-generation HDAC and DNMT inhibitors mature in the clinic, the next wave of R&D is targeting highly selective PROTACs and novel bromodomain inhibitors for solid tumors and hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Novartis, Merck | Hematological Cancers | Enzymatic Assay Substrate (Need high-purity H4C4 protein) |
| PROTAC / Degrader | Arvinas, Kymera | Solid Tumors | Binding & Ternary Complex Assay (Need Sequence Verified targets) |
| Epigenetic Reader Inhibitor | Bayer, Epizyme | Lymphoma | Reader Domain Interaction (Need reliable Acetylated/Modified H4 references) |